anti-BCMA

Anti-BCMA refers to a broad category of therapeutic agents designed to target the B-cell maturation antigen (BCMA), also known as TNFRSF17. BCMA is a cell surface receptor highly expressed on malignant plasma cells in multiple myeloma, as well as on normal mature B lymphocytes and plasma cells, making it an ideal target for selective immunotherapy. The anti-BCMA landscape includes several distinct modalities: autologous and allogeneic chimeric antigen receptor (CAR) T-cell therapies, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates (ADCs). These agents work by binding to BCMA and either directly delivering a cytotoxic payload or recruiting and activating immune effector cells (such as T cells or NK cells) to eliminate the target cell. While primarily developed for relapsed or refractory multiple myeloma, anti-BCMA therapies are increasingly being explored for newly diagnosed patients and for the treatment of B-cell mediated autoimmune diseases such as immune thrombocytopenia (ITP) and IgG4-related disease.

Other names

anti-B-cell maturation antigenBCMA-targeted therapyBCMA-directed therapyanti-BCMA CAR-TBCMA-CART